Table 2.

The clinical significance of CD73 in cancer patients.

Cancer type	Number of patients	Clinical implication of CD73	Reference
Colorectal cancer	358	Overexpression of CD73 is an independent poor prognostic biomarker for human CRC	[16, 17]
Epithelial ovarian carcinoma	167	Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, and better differentiation	[18]
Gastric cancer	68	CD73 overexpression was positively correlated with differentiation of tumor, histopathology, depth of invasion, nodal status, metastasis, cancer stage, and low overall survival rate of patients	[19]
Gallbladder cancer	108	Survival time of patients with NT5E expression was significantly shorter than those without NT5E expression	[20]
Leukemia	86	Expression of CD73 was associated with leukemia subtype, differentiation, and development	[21]
Chronic lymphoblastic leukemia	229	High expression of CD73 was associated with a more aggressive and proliferation disease	[22]
Acute lymphoblastic leukemia (children)	338	CD73 expression had no prognostic value in children with acute lymphoblastic leukemia	[23]
Prostate cancer	116	Overexpression of CD73 in prostate cancer is associated with lymph node metastasis	[24]
Malignant melanoma	52	CD73 expression is epigenetically regulated in malignant melanoma and associated with metastatic site specificity	[9]
Breast cancer (stages I–III)	136	Elevated CD73 expression in stages I–III breast cancer can predict a good prognosis	[25]
Triple negative breast cancer  Luminal breast cancer  HER2+ breast cancer	661  2083  487	CD73 gene expression was significantly associated with a worse prognosis in TNBC patients but not in patients with luminal or HER2+ breast cancer	[26]